Europace 2023 25 277282 httpsdoiorg101093europaceeuac214 CLINICAL RESEARCH Contemporary management atrial fibrillation predicted vs absolute risk ischaemic stroke despite treatment report ESCEHRA EORPAF LongTerm General Registry Wern Yew Ding Francisco Marin Gregory Y H Lip Registry Investigators 1 Carina BlomströmLundqvist 56 Giuseppe Boriani 4 Tatjana S Potpara 18 behalf ESCEHRA EORPAF LongTerm General 2 Laurent Fauchier 7 3 1Liverpool Centre Cardiovascular Science University Liverpool Liverpool Heart Chest Hospital Liverpool UK 2Department Cardiology School Medical Sciences Faculty Medicine Health Örebro University Örebro Sweden 3Service Cardiologie Centre Hospitalier Universitaire Trousseau Tours France 4Department Cardiology Hospital Universitario Virgen la Arrixaca IMIBArrixaca University Murcia CIBERCV Murcia Spain 5School Medicine University Belgrade Belgrade Serbia 6Intensive Arrhythmia Care Cardiology Clinic Clinical Center Serbia Belgrade Serbia 7Cardiology Division Department Biomedical Metabolic Neural Sciences University Modena Reggio Emilia Policlinico di Modena Modena Italy 8Aalborg Thrombosis Research Unit Department Clinical Medicine Aalborg University Aalborg Denmark Received 28 June 2022 accepted revision 30 September 2022 online publishaheadofprint 25 November 2022 Background Risk stratification patients atrial fibrillation AF important facilitate guidelinedirected therapies The Calculator Absolute Stroke Risk CARS scheme enables individualized estimation 1year absolute risk stroke AF We aimed investigate predicted absolute risks ischaemic stroke evaluate CARS CHA2DS2 VASc score useful identifying high risk patients AF despite contemporary treatment Methods We utilized EORPAF General LongTerm Registry prospectively enrolled patients AF 250 centres 27 participating European countries Patients sufficient data determine CARS CHA2DS2VASc score reported outcomes ischaemic stroke included analysis The primary outcome ischaemic stroke recorded 2year followup period Results A total 9444 patients included mean age 691 114 years 3776 400 females There high uptake 879 anticoagulation therapy predominantly vitamin K antagonist 500 Over mean followup period 24 months total 101 11 ischaemic stroke events In entire cohort median CARS absolute annual risks ischaemic stroke 260 IQR 160400 053 95CI 043064 respectively There stat istical difference predictive performance CARS CHA2DS2VASc score 0621 95CI 05630678 vs 0626 95CI 05730680 P 0725 Conclusion Contemporary management AF associated low risk ischaemic stroke CARS CHA2DS2VASc score useful identify high risk patients despite treatment benefit aggressive treatment followup Keywords Atrial fibrillation Predictive stroke risk Absolute stroke risk Ischaemic stroke CARS CHA2DS2VASc score EORPAF Corresponding author Tel 0151 794 9020 Email address gregorylipliverpoolacuk Joint senior authors The Authors 2022 Published Oxford University Press behalf European Society Cardiology This Open Access article distributed terms Creative Commons AttributionNonCommercial License httpscreativecommonsorglicensesbync40 permits noncommercial reuse distribution reproduction medium provided original work properly cited For commercial reuse contact journalspermissionsoupcom 278 WY Ding et al Whats new Contemporary management including anticoagulation patients atrial fibrillation associated reduction 86 absolute risk ischaemic stroke predicted CARS Both CARS CHA2DS2VASc score modest predictive cap ability absolute ischaemic stroke events anticoagulated patients atrial fibrillation The predictive capability CARS CHA2DS2VASc score The predictive capability CARS similar subgroups comparable ischaemic stroke events CHA2DS2VASc risk category anticoagulation therapy Introduction Atrial fibrillation AF associated significant risk thrombo embolism doubling mortality rate increased hospita lizations healthcare costs12 Management patients AF includes detailed stroke risk assessment typically performed CHA2DS2VASc score3 The information derived assess ment guide prescription anticoagulation ther apy45 traditionally established treatment associated prognostic benefit AF However emerging evidence suggest appropriate characterization evaluation67 followed holistic integrated care management approach8 early rhythm control910 offer survival advantage Hence important determine residual risk stroke pa tients receiving contemporary treatment AF identify benefit additional forms intervention Yet currently validated model purpose Recently Lee et al proposed Calculator Absolute Stroke Risk CARS enables individualized estimation 1year absolute risk stroke AF11 CARS derived large realworld retro spective Danish cohort nonanticoagulated patients 1997 2015 firstdiagnosed AF It utilizes risk factors CHA2DS2VASc score analyses age continuous variable considers individual contribution risk factors The role CARS prospective cohort patients receiving treatment AF remains determined Herein aimed investigate predicted absolute risks ischaemic stroke evaluate CARS CHA2DS2VASc score useful identifying high risk patients prospective cohort patients AF receiving contemporary management We investigated European Society CardiologyEuropean Heart Rhythm Association ESCEHRA EURObservational Research Programme EORPAF General LongTerm Registry Methods The EORPAF General LongTerm Registry prospective observational largescale multicentre registry 250 centres 27 participating European countries A detailed description study design previous ly provided12 In brief patients AF presented cardiology services enrolled October 2013 September 2016 All patients 18 years old electrocardiographic confirmation AF 12 months enrolment Institutional review board approval study protocol obtained institution study performed accordance European Union Note Guidance Good Clinical Practice CPMPECH13595 Declaration Helsinki For purposes analysis included patients sufficient data calculate individual CARS CHA2DS2VASc score missing information outcome ischaemic stroke Table 1 Baseline characteristics Baseline characteristics n 9444 Age years mean SD Female sex n BMI kgm2 mean SD eGFR mLmin173 m2 mean SD LA diameter mm mean SD LV ejection fraction mean SD Left ventricular hypertrophy n AF classification n Firstdetected Paroxysmal Persistent Longstanding persistent Permanent EHRA classification n I II III IV Comorbidities n Cardiomyopathy Congenital heart disease COPD Coronary artery disease Diabetes mellitus Heart failure Hypertension Liver disease Peripheral vascular disease Previous haemorrhagic event Previous thromboembolic event Previous ischaemic stroke Sleep apnoea Hyperthyroidism Hypothyroidism Valvular heart disease Prior catheter AF ablation n CHA2DS2VASc score mean SD HASBLED score mean SD 691 114 3776 400 283 51 694 212 454 82 537 130 2181 275 1452 156 2468 266 1850 199 420 45 3099 334 4283 454 3373 357 1592 169 196 21 1367 145 103 11 815 87 2551 283 2142 227 3569 378 5843 619 236 25 748 79 501 53 1093 116 572 61 440 48 168 18 511 55 4629 497 457 60 31 18 16 11 AF atrial fibrillation BMI body mass index COPD chronic obstructive pulmonary disease eGFR estimated glomerular filtration rate EHRA European Heart Rhythm Association LA left atrium LV left ventricle SD standard deviation Data demographics comorbidities medications collected baseline These determine predicted stroke risk CARS11 CHA2DS2VASc score Estimated glomerular filtration rate eGFR assessed Chronic Kidney DiseaseEpidemiology Collaboration CKDEPI equation Patients CHA2DS2VASc score 0 13 3 designated low risk high risk high risk respectively The predicted residual 1year stroke risk Predicted absolute ischaemic stroke risk AF 279 Table 2 Baseline medication use Table 3 Predicted vs absolute stroke risk Baseline medication use n 9444 Antithrombotic n Any antiplatelet Acetylsalicylic acid Clopidogrel Oral anticoagulants n Vitamin K antagonist Any NOAC Apixaban Dabigatran Edoxaban Rivaroxaban Heparin Antiarrhythmics n Amiodarone Flecainide Propafenone Sotalol Other medications n ACE inhibitors Aldosterone blockers Angiotensin receptor blocker Betablockers Dihydropyridine CCB Digoxin Diuretics Insulin Oral antidiabetics Statins 8876 940 1769 187 1588 168 547 58 8296 879 4721 500 3429 363 956 101 756 80 94 10 1623 172 146 15 2610 277 1638 174 341 36 325 35 275 29 3944 419 1673 178 1843 196 6529 694 1617 172 1321 140 4761 506 510 54 1425 151 3999 425 ACE angiotensin converting enzyme CCB calciumchannel blocker eGFR estimated glomerular filtration rate NOAC nonvitamin K antagonist oral anticoagulant mCARS estimated previously described13 For analysis primary study outcome ischaemic stroke This recorded 2year followup period Statistical analyses Continuous variables described mean standard deviation SD tested differences ttest normally distributed Nonparametric variables shown median IQR interquartile range Categorical variables described count percentage tested differences chisquared test Absolute stroke risk 1year ex pressed incidence risk 95 confidence intervals CI The predictive capability CARS absolute stroke risk 1year investigated receiveroperating characteristic ROC curves area curve AUC represent ability predict ischaemic stroke events The performance CARS tested CHA2DS2VASc score DeLongs test14 Further subgroup analyses performed accord ing stroke risk profile CHA2DS2VASc score oral anticoagulation agent vitamin K antagonist VKA nonvitamin K antagonist oral anti coagulant NOAC A twosided p value 005 considered statistically significant Statistical analyses performed SPSS CARS Mean SD Median IQR Range mCARS Mean SD Median IQR Range Absolute stroke risk Number events n Annual risk 95 CI 381 406 260 160400 0102410 137 146 094 058094 004868 101 053 043064 CARS Calculator Absolute Stroke Risk CI confidence interval IQR interquartile range SD standard deviation version 24 IBM Corp Armonk NY R version 403 R Foundation Statistical Computing Vienna Austria Results A total 9444 patients included present analysis corre sponding 851 original cohort 11 096 patients The mean age patients 691 114 years 3776 400 females Table 1 Majority patients permanent AF 334 mean left atrial diameter eGFR 454 82 mm 694 212 mLmin173 m2 respectively Few patients 190 severe symp toms based European Heart Rhythm Association symptom scale IIIIV The common comorbidities hypertension 619 valvular heart disease 497 heart failure 378 coronary artery disease 283 diabetes mellitus 227 cardiomyopathy 145 Mean CHA2DS2VASc score 31 18 There high uptake 879 anticoagulation therapy pre dominantly VKA 500 The use anticoagulation therapy ac cording CHA2DS2VASc score shown Supplementary material online Table S1 Rivaroxaban frequently 172 prescribed NOAC followed apixaban 101 dabigatran 80 edoxaban 10 Other medications baseline Table 2 Predicted vs absolute stroke risk Over mean followup period 24 months total 101 11 ischaemic stroke events In entire cohort absolute nual risk ischaemic stroke 053 95CI 043064 Table 3 The median CARS mCARS 260 IQR 160400 094 IQR 058094 respectively Based absolute risk ischaemic stroke 86 reduction predicted stroke risk cohort The relative risk reduction appeared pro nounced patients greater CHA2DS2VASc score Table 4 Predictive performance CARS CHA2DS2VASc score Receiveroperating characteristics curves absolute stroke events CARS CHA2DS2VASc score shown Figure 1 The AUCs CARS CHA2DS2VASc score 0621 95CI 05630678 vs 0626 95CI 05730680 respectively There statistical 280 WY Ding et al Table 4 Predicted vs absolute stroke risk stratified CHA2DS2VASc score CHA2DS2VASc score CARS mCARS Absolute stroke risk Mean SD Number events n Annual risk 95 CI Mean SD Range Range CHA2DS2VASc score 0 n 627 CHA2DS2VASc score 1 n 1225 CHA2DS2VASc score 2 n 1736 CHA2DS2VASc score 3 n 1959 CHA2DS2VASc score 4 n 1871 CHA2DS2VASc score 5 n 1171 CHA2DS2VASc score 6 n 550 CHA2DS2VASc score 7 n 219 CHA2DS2VASc score 8 n 74 CHA2DS2VASc score 9 n 12 068 080 0101060 025 029 004382 115 085 0101200 042 030 004432 200 137 0101710 072 049 004616 304 210 0101590 109 076 004572 435 303 0402010 157 109 014724 590 416 1002060 212 150 036742 945 566 2402270 340 204 086817 1369 526 3802410 493 189 137868 1690 199 13602220 608 072 490799 1763 162 15902100 635 058 572756 3 6 14 17 22 22 11 5 1 0 024 0051 024 005044 040 019061 043 023064 059 034083 094 055133 100 041159 114 014214 068 0202 NA CARS Calculator Absolute Stroke Risk CI confidence interval IQR interquartile range NA available SD standard deviation difference predictive performance CARS CHA2DS2VASc score P 0725 Subgroup analysis CHA2DS2VASc score risk category The predicted absolute stroke risks stratified CHA2DS2VASc score displayed Table 4 The mean CARS ranged 068 1763 absolute annual stroke risk ranged 024 114 In general CARS absolute annual stroke risk greater increasing CHA2DS2VASc score Figure 2 Patients low risk category score 0 absolute annual stroke risk 024 compared 038 high risk category score 13 078 high risk category score 3 Supplementary material online Table S2 Receiveroperating characteristic curves absolute stroke events CARS according CHA2DS2VASc risk category shown Supplementary material online Figure S1 The AUCs CARS low risk high risk high risk patients 0595 95CI 0361 0829 0512 95CI 04320592 0623 95CI 05530693 spectively There statistical difference AUCs risk category high risk vs low risk P 0444 high risk vs low risk P 0822 Subgroup analysis anticoagulation therapy The baseline characteristics subgroups treated VKA NOAC shown Supplementary material online Table S3 Patients VKA subgroup older higher prevalence manent AF worse echocardiographic parameters greater burden comorbidities As result mean CHA2DS2VASc HASBLED scores increased patients treated VKA compared NOAC CHA2DS2VASc 34 vs 31 P 0022 HASBLED 18 vs 14 P 0001 The mean CARS VKA subgroup 402 408 NOAC subgroup 378 411 Supplementary material online Table S4 The absolute annual stroke risk VKA NOAC sub groups 049 95CI 035063 024 95CI 016032 respectively Receiveroperating characteristic curves absolute stroke events patients receiving VKA vs NOAC therapy shown Supplementary material online Figure S2 The AUCs CARS VKA subgroup 633 95CI 549717 NOAC subgroup 671 95CI 575767 There statistical difference tween predictive performance CARS sub groups P 0557 Discussion The main findings study predominantly anticoagulated pa tients AF prospective multicentre registry 27 participat ing European countries follows 1 absolute risk ischaemic stroke 86 lower predicted risk CARS hort 2 CARS CHA2DS2VASc score modest predictive capability absolute ischaemic stroke events anticoagulated patients 3 predictive capability CARS CHA2DS2VASc score comparable ischaemic stroke events 4 predictive capabil ity CARS similar subgroups CHA2DS2VASc risk category anticoagulation therapy In contemporary cohort treated patients AF risk ischaemic stroke cohort lower compared predicted risk CARS Furthermore relative risk reduction predicted vs absolute ischaemic stroke risk appeared greater patients increased CHA2DS2VASc score The reduction risk ischaemic stroke likely driven high uptake oral anticoagulation ther apy known beneficial purpose AF Nonetheless observed risk reduction greater 64 previously ported metaanalysis comparing OAC use controls15 sug gesting interplay factors Although study designed compare effects contemporary vs historical treat ment AF patients postulated better understanding underlying pathophysiological mechanisms AF16 alongside implementation newer oral anticoagulation agents17 led improved outcomes condition In study evaluated use CARS CHA2DS2VASc score predict ischaemic stroke risk realworld patients Although CHA2DS2VASc score marginally better predictive score statistically significant The advantage CARS CHA2DS2VASc score situation modified mCARS provide individual risk estimate absolute risk easy interpret useful facilitate patientcentred dis cussions Furthermore CARS dynamic tool allows adjustment age continuous manner Predicted absolute ischaemic stroke risk AF 281 incorporated reported outcomes determine NNTnet number needed treat net effect combines benefitandharm intervention therapy20 Limitations The major limitation study relates observational nature misclassification bias Furthermore potential EORPAF General LongTerm Registry based exclusively cardi ology practices findings generalizable cohorts The annual absolute stroke risk determined assuming linear event rate 2 year followup period There ischaemic stroke events patients high CHA2DS2VASc score influenced results subgroup analysis Moreover somewhat arbitrary risk categories classify patients according CHA2DS2VASc score Conclusions Contemporary management patients AF cardiology practices Europe associated 86 relative risk reduction ischaemic stroke CARS CHA2DS2VASc score useful identify high risk patients despite treatment benefit aggressive treatment intensive followup CARS facilitate future research realworld cohorts registries determine impact specific treatments intervention baseline abso lute risk ischaemic stroke AF Supplementary material Supplementary material available Europace online Acknowledgements EORP Oversight Committee Executive Steering Committees National Coordinators EURObservational Research Programme EORPAtrial Fibrillation General LongTerm EORPAFGen LT Registry European Society Cardiology ESC Data collection conducted EORP department PattiAnn McNeill Project Officer Viviane Missiamenou Data Manager Overall activities ordinated supervised Doctor Aldo P Maggioni EORP Scientific Coordinator Funding Since start EORP following companies supported pro gramme Abbott Vascular Int 201121 Amgen Cardiovascular 2009 18 AstraZeneca 201421 Bayer 200918 Boehringer Ingelheim 200919 Boston Scientific 200912 The Bristol Myers Squibb Pfizer Alliance 201116 The Alliance Daiichi Sankyo Europe GmbH Eli Lilly Company 201117 Edwards 201619 Gedeon Richter Plc 201417 Menarini Int Op 200912 MSDMerck Co 2011 14 Novartis Pharma AG 201420 ResMed 201416 Sanofi 2009 11 SERVIER 201021 Vifor 201922 Conflict GB small speakers fees Medtronic Boston Biotronik Boehringer Bayer outside submitted work FM ceiving grants Ferrer personal fees Bayer PfizerBMS BoehringerIngelheim AstraZeneca outside submitted work CBL receiving grants Medtronic Cardiome personal fees Bayer Sanofi Boston Scientific Philips CathPrint Organon Merck Sharp Dohme outside submitted work TSP Consultant Bayer Pfizer fees LF consultant speaker activities small amounts AstraZeneca Bayer BMSPfizer Boehringer Ingelheim Medtronic Novartis Novo XO Zoll GYHL Consultant speaker BMSPfizer Boehringer Ingelheim DaiichiSankyo No fees ceived personally Other authors declare conflict Figure 1 Receiveroperating characteristic curves absolute stroke events CARS vs CHA2DS2VASc score Figure 2 Plot CARS vs absolute annual stroke risk stratified CHA2DS2VASc score Using CARS CHA2DS2VASc score patients high residual risk ischaemic stroke despite treatment1819 identified intensive followup holistic management strategies Indeed adherence guidelinerecommended Atrial fibrillation Better Care ABC pathway associated 45 reduction ischaemic stroke compared nonadherence8 To reinforce possible role CARS demonstrated individualized predictive cap ability tool maintained regardless CHA2DS2VASc risk category choice anticoagulation therapy Additionally calcu lated baseline absolute risk CARS estimate impact specific treatments study cohorts It 100806040Sensitivity 2000204060100 Specificity CARSCHA2DS2VAScAUC 621AUC 6268010020012108642016012080400012345Absolute annual stroke risk CARS 6CHA2DS2VASc score78 282 WY Ding et al Data availability The data underlying article shared reasonable request corresponding author Appendix 1 EURObservational Research Programme Atrial Fibrillation EORPAF LongTerm General Registry Committees Investigators ESC Member Countries Executive committee GBoriani Chair GYH Lip L Tavazzi A P Maggioni GA Dan T Potpara M Nabauer F Marin Z Kalarus L Fauchier Steering Committee National Coordinators A Goda G Mairesse TShalganov L Antoniades M Taborsky S Riahi P Muda I García Bolao O Piot M Nabauer K Etsadashvili ESimantirakis M Haim A Azhari J Najafian M Santini E Mirrakhimov Ka Kulzida A Erglis L Poposka M Burg H Crijns Ö Erküner D Atar R Lenarczyk M Martins Oliveira D Shah GA Dan E Serdechnaya T Potpara E Diker GYH Lip D Lane Participants ALBANIA Durrës E Zëra Tirana U Ekmekçiu V Paparisto M Tase Tirana H Gjergo J Dragoti A Goda BELGIUM Bastogne M Ciutea N Ahadi Z el Husseini M Raepers Gilly J Leroy P Haushan A Jourdan Haine Saint Paul C Lepiece Hasselt L Desteghe J Vijgen P Koopman G Van Genechten H Heidbuchel Kortrijk T Boussy M De Coninck H Van Eeckhoutte N Bouckaert La Louviere A Friart J Boreux C Arend Liege P Evrard Liège L Stefan E Hoffer J Herzet M Massoz Liège C Celentano M Sprynger L Pierard Liège P Melon Overpelt B Van Hauwaert C Kuppens D Faes D Van Lier A Van Dorpe Waremme A Gerardy Yvoir O Deceuninck O Xhaet F Dormal E Ballant D Blommaert BULGARIA Pleven D Yakova M Hristov T Yncheva N Stancheva S Tisheva Plovdiv M Tokmakova F Nikolov D Gencheva Sofia T Shalganov B Kunev M Stoyanov Sofia D Marchov V Gelev V Traykov Varna A Kisheva H Tsvyatkov R Shtereva S BakalskaGeorgieva S Slavcheva Y Yotov CZECH REPUBLIC Ústí nad Labem M Kubíčková DENMARK Aalborg A Marni Joensen A Gammelmark L Hvilsted Rasmussen P Dinesen S Riahi S Krogh Venø B Sorensen A Korsgaard K Andersen C Fragtrup Hellum Esbjerg A Svenningsen O Nyvad P Wiggers Herning O May A Aarup B Graversen L Jensen M Andersen M Svejgaard S Vester S Hansen V Lynggaard Madrid M Ciudad Tallinn R Vettus Tartu P Muda ESTONIA Elche Alicante A Maestre Toledo S Castaño FRANCE Abbeville S Cheggour Abbeville J Poulard V Mouquet S Leparrée AixenProvence J Bouet J Taieb Amiens A Doucy H Duquenne Angers A Furber J Dupuis J Rautureau Aurillac M Font P Damiano Avignon Cedex M Lacrimini Brest J Abalea S Boismal T Menez J Mansourati Chartres G Range H Gorka C Laure C Vassalière Creteil N Elbaz N Lellouche K Djouadi Montpellier F Roubille D Dietz J Davy Nimes M Granier P Winum C LeperchoisJacquey Paris H Kassim E Marijon J Le Heuzey Paris J Fedida C Maupain C Himbert E Gandjbakhch F HiddenLucet G Duthoit N Badenco T Chastre X Waintraub M Oudihat J Lacoste C Stephan Pau H Bader N Delarche L Giry Pessac D Arnaud C Lopez F Boury I Brunello M Lefèvre R Mingam M Haissaguerre Rennes M Le Bidan D Pavin V Le Moal C Leclercq Saint Denis O Piot T Beitar Saint Etienne I Martel A Schmid N Sadki C RomeyerBouchard A Da Costa Tours I Arnault M Boyer C Piat L Fauchier FYR MACEDONIA Bitola N Lozance S Nastevska Ohrid A Doneva B Fortomaroska Milevska B Sheshoski K Petroska N Taneska N Bakrecheski Skopje K Lazarovska S Jovevska V Ristovski A Antovski Skopje E Lazarova I Kotlar J Taleski L Poposka S Kedev Skopje N Zlatanovik Štip S Jordanova T Bajraktarova Proseva S Doncovska GEORGIA Tbilisi D Maisuradze A Esakia E Sagirashvili K Lartsuliani N Natelashvili N Gumberidze R Gvenetadze Tbilisi K Etsadashvili N Gotonelia N Kuridze Tbilisi G Papiashvili I Menabde GERMANY Aachen S Glöggler A Napp C Lebherz H Romero K Schmitz M Berger M Zink S Köster J Sachse E Vonderhagen G Soiron K Mischke Bad Reichenhall R Reith M Schneider Berlin W Rieker Biberach D Boscher A Taschareck A Beer Boppard D Oster Brandenburg O Ritter J Adamczewski S Walter Chemnitz A Frommhold E Luckner J Richter M Schellner S Landgraf S Bartholome Chemnitz R Naumann J Schoeler Dachau D Westermeier F William K Wilhelm M Maerkl Detmold R Oekinghaus M Denart M Kriete U Tebbe Ebersbach T Scheibner Erlangen M Gruber A Gerlach C Beckendorf L Anneken M Arnold S Lengerer Z Bal C Uecker H Förtsch S Fechner V Mages Friedberg E Martens H Methe Göttingen T Schmidt Hamburg B Schaeffer B Hoffmann J Moser K Heitmann S Willems S Willems Hartmannsdorf C Klaus I Lange Heidelberg M Durak E Esen Itzehoe F Mibach H Mibach Kassel A Utech Kirchzarten M Gabelmann R Stumm V Ländle Koblenz C Gartner C Goerg N Kaul S Messer D Burkhardt C Sander R Orthen S Kaes Köln A Baumer F Dodos Königsbrück A Barth G Schaeffer Leisnig J Gaertner J Winkler Leverkusen A Fahrig J Aring I Wenzel Limburg S Steiner A Kliesch E Kratz K Winter P Schneider Ludwigsburg A Haag I Mutscher R Bosch Markkleeberg J Taggeselle S Meixner Meissen A Schnabel Meppen A Shamalla H Hötz A Korinth Merzig C Rheinert Moosburg G Mehltretter Mühldorf B Schön N Schön A Starflinger E Englmann Munich G Baytok T Laschinger G Ritscher Munich A Gerth Münster D Dechering L Eckardt Nienburg M Kuhlmann N Proskynitopoulos Paderborn J Brunn K Foth Pirna C Axthelm H Hohensee K Eberhard S Turbanisch Plauen N Hassler A Koestler Riesa G Stenzel Riesa D Kschiwan M Schwefer S Neiner S Hettwer Rotenburg ad Fulda M HaeusslerSchuchardt R Degenhardt S Sennhenn S Steiner Starnberg M Brendel Westerstede A Stoehr W Widjaja S Loehndorf A Logemann J Hoskamp J Grundt Zorneding M Block Zwiesel R Ulrych A Reithmeier V Panagopoulos ITALY Bologna C Martignani D Bernucci E Fantecchi I Diemberger M Ziacchi M Biffi P Cimaglia J Frisoni G Boriani Firenze I Giannini S Boni S Fumagalli S Pupo A Di Chiara P Mirone Modena E Fantecchi G Boriani F Pesce C Zoccali VLMalavasi KAZAKHSTAN Almaty A Mussagaliyeva B Ahyt Z Salihova K KoshumBayeva KYRGYZSTAN Bishkek A Kerimkulova A Bairamukova E Mirrakhimov LATVIA Riga B Lurina R Zuzans S Jegere I Mintale K Kupics K Jubele A Erglis O Kalejs MALTA Birkirkara K Vanhear M Burg M Cachia E Abela S Warwicker T Tabone R Xuereb MONTENEGRO Podgorica D Asanovic D Drakalovic M Vukmirovic N Pavlovic L Music N Bulatovic A Boskovic NETHERLANDS Almere H Uiterwaal N Bijsterveld Amsterdam J De Groot J Neefs N van den Berg F Piersma A Wilde Delfzijl V Hagens Enschede J Van Es J Van Opstal B Van Rennes H Verheij W Breukers Heerenveen G Tjeerdsma R Nijmeijer D Wegink R Binnema Hengelo S Said Maastricht Ö Erküner S Philippens W van Doorn H Crijns Rotterdam T SziliTorok R Bhagwandien P Janse A Muskens sHertogenbosch M van Eck R Gevers N van der Ven Venlo A Duygun B Rahel J Meeder NORWAY Oslo A Vold C Holst Hansen I Engset D Atar POLAND Bytom B DyduchFejklowicz E Koba M Cichocka Cieszyn A Sokal A Kubicius E Pruchniewicz Gliwice A KowalikSztylc W Czapla Katowice I Mróz M Kozlowski T Pawlowski M Tendera Katowice A WiniarskaFilipek A Fidyk A Slowikowski M Haberka M LachorBroda M Biedron Z Gasior Kielce M Kołodziej M I GorczycaMichta B WozakowskaKaplon Łódź M Stasiak P Jakubowski T Ciurus Janion Kielce Predicted absolute ischaemic stroke risk AF 282a J Drozdz Łódź M Simiera P Zajac T Wcislo P Zycinski J Kasprzak Nysa A Olejnik E HarcDyl J Miarka M Pasieka M ZiemińskaŁuć W Bujak Opoczno A Śliwiński A Grech J Morka K Petrykowska M Prasał Opole G Hordyński P Feusette P Lipski A Wester Radlin W Streb Rzeszów J Romanek P Woźniak M Chlebuś P Szafarz W Stanik Szczecin M Zakrzewski J Kaźmierczak Szczecin A Przybylska E Skorek H Błaszczyk M Stępień S Szabowski W Krysiak M Szymańska Tarnów J Karasiński J Blicharz M Skura Warsaw K Hałas L Michalczyk Z Orski K Krzyżanowski A Skrobowski Warsaw L Zieliński M TomaszewskaKiecana M Dłużniewski Warsaw M Kiliszek M Peller M Budnik P Balsam G Opolski A Tymińska K Ozierański A Wancerz Warsaw A Borowiec E Majos R Dabrowski H Szwed Zabrze A MusialikLydka Zabrze A LeopoldJadczyk E JedrzejczykPatej M Koziel R Lenarczyk M Mazurek Z Kalarus Zabrze K KrzemienWolska P Starosta E NowalanyKozielska Zakopane A Orzechowska M Szpot M Staszel PORTUGAL Almada S Almeida H Pereira L Brandão Alves R Miranda L Ribeiro Carnaxide Lisboa F Costa F Morgado P Carmo P Galvao Santos R Bernardo P Adragão Santarém G Ferreira da Silva M Peres M Alves M Leal Vila Real A Cordeiro P Magalhães P Fontes S Leão Viseu A Delgado A Costa B Marmelo B Rodrigues D Moreira J Santos L Santos ROMANIA Arad A Terchet D Darabantiu S Mercea V Turcin Halka A Pop Moldovan Brasov A Gabor B Doka G Catanescu H Rus L Oboroceanu E Bobescu Bucharest R Popescu A Dan A Buzea I Daha G Dan I Neuhoff Bucharest M Baluta R Ploesteanu N Dumitrache M Vintila Bucharest A Daraban C Japie E Badila H Tewelde M Hostiuc S Frunza E Tintea D Bartos Bucharest A Ciobanu I Popescu N Toma C Gherghinescu D Cretu N Patrascu C Stoicescu C Udroiu G Bicescu V Vintila D Vinereanu M Cinteza R Rimbas Iași M Grecu Oradea A Cozma F Boros M Ille O Tica R Tor A Corina A Jeewooth B Maria C Georgiana C Natalia D Alin D DinuAndrei M Livia R Daniela R Larisa S Umaar T Tamara M Ioachim Popescu Târgu Mureș D Nistor I Sus O Coborosanu Timișoara N AlinaRamona R Dan L Petrescu Timișoara G Ionescu I Popescu C Vacarescu E Goanta M Mangea A Ionac C Mornos D Cozma S Pescariu RUSSIAN FEDERATION Arkhangelsk E Solodovnicova I Soldatova J Shutova L Tjuleneva T Zubova V Uskov Arkhangelsk D Obukhov G Rusanova Arkhangelsk I Soldatova N Isakova S Odinsova T Arhipova Arkhangelsk E Kazakevich E Serdechnaya O Zavyalova SaintPetersburg T Novikova SaintPetersburg I Riabaia S Zhigalov SaintPetersburg E Drozdova I Luchkina Y Monogarova Vladivostok D Hegya L Rodionova L Rodionova V Nevzorova Vladivostok I Soldatova O Lusanova SERBIA Belgrade A Arandjelovic D Toncev L Vukmirovic M Radisavljevic M Milanov N Sekularac Belgrade M Zdravkovic S Hinic S Dimkovic T Acimovic J Saric S Radovanovic Belgrade A Kocijancic B ObrenovicKircanski D Kalimanovska Ostric D Simic I Jovanovic I Petrovic M Polovina M Vukicevic M Tomasevic N Mujovic N Radivojevic O Petrovic S Aleksandric V Kovacevic Z Mijatovic B Ivanovic M Tesic T Potpara A Ristic B VujisicTesic M Nedeljkovic Belgrade A Karadzic A Uscumlic M Prodanovic M Zlatar M Asanin Belgrade B Bisenic V Vasic Z Popovic Belgrade D Djikic M Sipic V Peric B Dejanovic N Milosevic Belgrade S Backovic A Stevanovic A Andric B Pencic M PavlovicKleut V Celic Kragujevac M Pavlovic M Petrovic M Vuleta N Petrovic S Simovic Z Savovic S Milanov G Davidovic V IricCupic Niš D Djordjevic M Damjanovic Stanojevic M Randjelovic S Zdravkovic V Topic D R JankovicTomasevic V Atanaskovic S Antic M Pavlovic Niška Banja D Simonovic M Stojanovic S Stojanovic V Mitic V Ilic D Petrovic M Deljanin Ilic S Ilic V Stoickov Pirot S Markovic Šabac A Mijatovic D Tanasic D Petrovic G Radakovic J Peranovic M Pavlovic N PanicJelic O Vujadinovic P Pajic S Bekic S Kovacevic SPAIN Alicante A García Fernandez Benalmadena A Perez Cabeza Córdoba M Anguita Granada L Tercedor Sanchez Huarte E Mau J Loayssa M Ayarra M Carpintero Madrid I Roldán Rabadan Murcia M Leal Murcia M Gil Ortega Murcia A Tello Montoliu E Orenes Piñero S Manzano Fernández F Marín A Romero Aniorte A Veliz Martínez M Quintana Giner Pamplona G Ballesteros M Palacio O Alcalde I GarcíaBolao San Juan Alicante V Bertomeu Gonzalez Santiago Compostela F OteroRaviña J García Seara J Gonzalez Juanatey SWITZERLAND Geneva N Dayal P Maziarski P GentilBaron D Shah TURKEY Adana M Koç Afyon E Onrat I E Dural Ankara K Yilmaz B Özin Ankara S Tan Kurklu Y Atmaca Ankara U Canpolat L Tokgozoglu Ankara A K Dolu B Demirtas D Sahin Ankara O Ozcan Celebi E Diker Antalya G Gagirci BayraklıIzmir UOTurk Bursa H Ari Diyarbakır N Polat N Toprak Gaziantep M Sucu GörükleBursa O Akin Serdar Istanbul A Taha Alper Istanbul A Kepez Istanbul Y Yuksel Kurupelit Samsun A Uzunselvi S Yuksel M Sahin MerkezDüzce O Kayapinar Mersin T Ozcan Sivas H Kaya M B Yilmaz Trabzon M Kutlu YüreğirAdana M Demir UNITED KINGDOM Barnstaple C Gibbs S Kaminskiene M Bryce A Skinner G Belcher J Hunt L Stancombe B Holbrook C Peters S Tettersell Birmingham A Shantsila D Lane K Senoo M Proietti K Russell P Domingos S Hussain J Partridge R Haynes S Bahadur R Brown S McMahon G Y H Lip Blackburn J McDonald K Balachandran R Singh S Garg H Desai K Davies W Goddard Blackpool G Galasko I Rahman Y Chua O Payne S Preston O Brennan L Pedley C Whiteside C Dickinson J Brown K Jones L Benham R Brady Carlisle L Buchanan A Ashton H Crowther H Fairlamb S Thornthwaite C Relph A McSkeane U Poultney N Kelsall P Rice T Wilson Chertsey M Wrigley R Kaba T Patel E Young J Law Cramlington C Runnett H Thomas H McKie J Fuller S Pick Exeter A Sharp A Hunt K Thorpe C Hardman E Cusack L Adams M Hough S Keenan A Bowring J Watts Great Yarmouth J Zaman K Goffin H Nutt Harrogate Y Beerachee J Featherstone C Mills J Pearson L Stephenson Huddersfield S Grant A Wilson C Hawksworth I Alam M Robinson S Ryan Macclesfield R Egdell E Gibson M Holland D Leonard Maidstone B Mishra S Ahmad H Randall J Hill L Reid M George S McKinley L Brockway W Milligan Manchester J Sobolewska J Muir L Tuckis L Winstanley P Jacob S Kaye L Morby Nottingham A Jan T Sewell Poole C Boos B Wadams C Cope P Jefferey Portsmouth N Andrews A Getty A Suttling C Turner K Hudson R Austin S Howe Redhill R Iqbal N Gandhi K Brophy P Mirza E Willard S Collins N Ndlovu Rhyl E Subkovas V Karthikeyan L Waggett A Wood A Bolger J Stockport L Evans E Harman J Starling L Williams V Saul Salisbury M Sinha L Bell S Tudgay S Kemp J Brown L Frost Shrewsbury T Ingram A Loughlin C Adams M Adams F Hurford C Owen C Miller D Donaldson H Tivenan H Button South Shields A Nasser O Jhagra B Stidolph C Brown C Livingstone M Duffy P Madgwick Southampton P Roberts E Greenwood L Fletcher M Beveridge S Earles Taunton D McKenzie D Beacock M Dayer M Seddon D Greenwell F Luxton F Venn H Mills J Rewbury K James K Roberts L Tonks Torquay D Felmeden W Taggu A Summerhayes D Hughes J Sutton L Felmeden Watford M Khan E Walker L Norris L ODonohoe WestonsuperMare A Mozid H Dymond H LloydJones G Saunders D Simmons D Coles D Cotterill S Beech S Kidd Wolverhampton B Wrigley S Petkar A Smallwood R Jones E Radford S Milgate S Metherell V Cottam Yeovil C Buckley A Broadley D Wood J Allison K Rennie L Balian L Howard L Pippard S Board T PittKerby 282b WY Ding et al References 1 Chugh SS Havmoeller R Narayanan K Singh D Rienstra M Benjamin EJ et al Worldwide epidemiology atrial fibrillation global burden disease 2010 study Circulation 201412983747 2 Burdett P Lip GYH Atrial fibrillation United Kingdom predicting costs emerging epidemic recognising forecasting cost drivers atrial fibrillation related costs Eur Hear J Qual Care Clin Outcomes 2022818794 3 Lip GYH Nieuwlaat R Pisters R Lane DA Crijns HJGM Refining clinical risk stratifica tion predicting stroke thromboembolism atrial fibrillation novel risk factorbased approach The Euro Heart Survey atrial fibrillation Chest 2010137 26372 4 Hindricks G Potpara T Dagres N Arbelo E Bax JJ BlomströmLundqvist C et al 2020 ESC Guidelines diagnosis management atrial fibrillation developed col laboration European Association CardioThoracic Surgery EACTS Eur Heart J 202142373498 5 Chao TF Joung B Takahashi Y Lim TW Choi EK Chan YH et al 2021 Focused update consensus guidelines Asia pacific heart rhythm society stroke prevention atrial fibrillation executive summary Thromb Haemost 20221222047 6 Potpara TS Lip GYH BlomstromLundqvist C Boriani G Van Gelder IC Heidbuchel H et al The 4SAF scheme stroke risk symptoms severity burden substrate novel approach indepth characterization classification atrial fibrillation Thromb Haemost 20211212708 7 Ding WY Proietti M Boriani G Fauchier L BlomströmLundqvist C Marin F et al Clinical utility prognostic implications novel 4SAF scheme characterize evaluate patients atrial fibrillation report ESCEHRA EORPAF LongTerm General Registry EP Europace 2022247218 8 Romiti GF Pastori D RiveraCaravaca JM Ding WY Gue YX Menichelli D et al Adherence atrial fibrillation better care pathway patients atrial fibrilla tion impact clinical outcomesA systematic review metaanalysis 285000 pa tients Thromb Haemost 202212240614 9 Kirchhof P Camm AJ Goette A Brandes A Eckardt L Elvan A et al Early rhythm control therapy patients atrial fibrillation N Engl J Med 2020383130516 10 Ding WY Calvert P Gupta D Huisman M V Lip GYH Impact early ablation atrial fibrillation longterm outcomes results phase IIIII GLORIAAF registry Clin Res Cardiol 2022111105768 11 Lee CJY ToftPetersen AP Ozenne B Phelps M Olesen JB Ellinor PT et al Assessing absolute stroke risk patients atrial fibrillation risk factor based approach Eur Hear J Cardiovasc Pharmacother 20219f3f10 12 Boriani G Proietti M Laroche C Fauchier L Marin F Nabauer M et al Contemporary stroke prevention strategies 11 096 European patients atrial fibrillation report EURObservational Research Programme Atrial Fibrillation EORPAF longterm general registry Europace 20182074757 13 Ding WY RiveraCaravaca JM Marin F TorpPedersen C Roldán V Lip GYH Prediction residual stroke risk anticoagulated patients atrial fibrillation mCARS J Clin Med 2021103357 14 DeLong ER DeLong DM ClarkePearson DL Comparing areas correlated receiver operating characteristic curves nonparametric approach Biometrics 19884483745 15 Hart RG Pearce LA Aguilar MI Metaanalysis antithrombotic therapy prevent stroke patients nonvalvular atrial fibrillation Ann Intern Med 2007146 85767 16 Ding WY Gupta D Lip GYH Atrial fibrillation prothrombotic state revisiting Virchows triad 2020 Heart 202010614638 17 Ruff CT Giugliano RP Braunwald E Hoffman EB Deenadayalu N Ezekowitz MD et al Comparison efficacy safety new oral anticoagulants warfarin pa tients atrial fibrillation metaanalysis randomised trials Lancet 2014383 95562 18 Ding WY Lane DA Gupta D Huisman MV Lip GYH Incidence risk factors sidual adverse events despite anticoagulation atrial fibrillation results phase IIIII GLORIAAF registry J Am Heart Assoc 202211e026410 19 Ding WY Residual stroke risk atrial fibrillation Arrhythmia Electrophysiol Rev 202110 14753 20 Ding WY RiveraCaravaca JM Marín F Li G Roldán V Lip GYH Number needed treat net effect anticoagulation atrial fibrillation realworld vs clinicaltrial evi dence Br J Clin Pharmacol 2022882829